全文获取类型
收费全文 | 12909篇 |
免费 | 979篇 |
国内免费 | 115篇 |
专业分类
耳鼻咽喉 | 93篇 |
儿科学 | 440篇 |
妇产科学 | 404篇 |
基础医学 | 1757篇 |
口腔科学 | 270篇 |
临床医学 | 1107篇 |
内科学 | 2484篇 |
皮肤病学 | 211篇 |
神经病学 | 909篇 |
特种医学 | 459篇 |
外科学 | 2259篇 |
综合类 | 588篇 |
一般理论 | 4篇 |
预防医学 | 697篇 |
眼科学 | 338篇 |
药学 | 734篇 |
1篇 | |
中国医学 | 78篇 |
肿瘤学 | 1170篇 |
出版年
2023年 | 125篇 |
2022年 | 65篇 |
2021年 | 300篇 |
2020年 | 235篇 |
2019年 | 306篇 |
2018年 | 334篇 |
2017年 | 263篇 |
2016年 | 289篇 |
2015年 | 348篇 |
2014年 | 442篇 |
2013年 | 541篇 |
2012年 | 858篇 |
2011年 | 915篇 |
2010年 | 547篇 |
2009年 | 472篇 |
2008年 | 721篇 |
2007年 | 683篇 |
2006年 | 710篇 |
2005年 | 701篇 |
2004年 | 670篇 |
2003年 | 592篇 |
2002年 | 552篇 |
2001年 | 513篇 |
2000年 | 409篇 |
1999年 | 347篇 |
1998年 | 101篇 |
1997年 | 97篇 |
1996年 | 83篇 |
1995年 | 85篇 |
1994年 | 65篇 |
1993年 | 53篇 |
1992年 | 162篇 |
1991年 | 149篇 |
1990年 | 161篇 |
1989年 | 158篇 |
1988年 | 131篇 |
1987年 | 139篇 |
1986年 | 108篇 |
1985年 | 86篇 |
1984年 | 53篇 |
1983年 | 44篇 |
1981年 | 34篇 |
1980年 | 29篇 |
1979年 | 52篇 |
1978年 | 37篇 |
1977年 | 32篇 |
1976年 | 26篇 |
1975年 | 24篇 |
1974年 | 21篇 |
1973年 | 26篇 |
排序方式: 共有10000条查询结果,搜索用时 109 毫秒
1.
2.
Bobo H. P. Lau Ting-Kin Ng Yat-Lui Fung Tai-Chung Lam Tsz-Him So 《Journal of psychosocial oncology》2020,38(4):389-405
AbstractPurposes/objectives: This paper reports the comparative efficacies of integrative body-mind-spirit intervention (I-BMS) and cognitive behavioral therapy (CBT) in patient-caregiver parallel groups for Chinese patients with lung cancer.Design: Randomized controlled trial (RCT).Methods: One hundred and fifty-seven patient-caregiver dyads with no marked functional impairment were randomized into one of the two interventions with eight weekly patient-caregiver parallel groups. Assessments were conducted at baseline, within one, eight- and sixteen-weeks post-intervention. Effects of treatment group across time were analyzed by multilevel modeling.Findings: CBT led to greater reduction in emotional vulnerability than I-BMS. I-BMS resulted in greater increase in overall QoL and spiritual self-care, and more reduction in depression than CBT. Patients in both interventions experienced improvement in physical, emotional and spiritual, except social, domains of QoL.Conclusion: I-BMS was more efficacious for diverse domains of QoL, and CBT was more effective for emotional well-being, despite the relatively small between-group effect sizes.Implications for psychosocial providers/policy: (1) With the expanding repertoire of psychosocial interventions for families facing lung cancer, it has become imperative to investigate the comparative efficacies of empirically supported and culturally adapted interventions. (2) Our findings show that I-BMS was more effective for diverse domains of QoL, while CBT was more efficacious with emotional well-being, although both interventions led to significant improvements in physical, emotional and spiritual domains of patient QoL. (3) Patient-caregiver parallel groups have been shown to be effective for enhancing QoL of Chinese lung cancer patients. (4) Care professionals are encouraged to dispense interventions based on the idiosyncratic needs and preferences of the patients to maximize the treatment effects. 相似文献
3.
Doreen A. Ezeife MD Francois Dionne PhD Aline Fusco Fares MD Ellen Laura Rose Cusano MD Rouhi Fazelzad BSc MISt Wenzie Ng BSc MPharm RPh Don Husereau BSc Pharm MSc Farzad Ali BPharm MSc Christina Sit MSc Barry Stein B.Com BCL LLB Jennifer H. Law MSc Lisa Le MSc Peter Michael Ellis MD MMed PhD Scott Berry MD Stuart Peacock PhD Craig Mitton PhD Craig C. Earle MD Kelvin K. W. Chan MD PhD Natasha B. Leighl MD MMSc 《Cancer》2020,126(7):1530-1540
4.
Fabian Falkenstein Marco Gessi Daniela Kandels Ho-Keung Ng René Schmidt Monika Warmuth-Metz Brigitte Bison Juergen Krauss Rolf-Dieter Kortmann Beate Timmermann Ulrich-Wilhelm Thomale Michael H. Albert Arnulf Pekrun Eberhard Maaß Astrid K. Gnekow Torsten Pietsch 《International journal of cancer. Journal international du cancer》2020,147(8):2159-2175
Reports on pediatric low-grade diffuse glioma WHO-grade II (DG2) suggest an impaired survival rate, but lack conclusive results for genetically defined DG2-entities. We analyzed the natural history, treatment and prognosis of DG2 and investigated which genetically defined sub-entities proved unfavorable for survival. Within the prospectively registered, population-based German/Swiss SIOP-LGG 2004 cohort 100 patients (age 0.8-17.8 years, 4% neurofibromatosis [NF1]) were diagnosed with a DG2. Following biopsy (41%) or variable extent of resection (59%), 65 patients received no adjuvant treatment. Radiologic progression or severe neurologic symptoms prompted chemotherapy (n = 18) or radiotherapy (n = 17). Multiple lines of salvage treatment were necessary for 19/35 patients. Five years event-free survival dropped to 0.44, while 5 years overall survival was 0.90 (median observation time 8.3 years). Extensive genetic profiling of 65/100 DG2 identified Histone3-K27M-mutation in 4, IDH1-mutation in 11, BRAF-V600-mutation in 12, KIAA1549-BRAF-fusions in 6 patients, while the remaining 32 tumor tissues did not show alterations of these genes. Progression to malignant glioma occurred in 12 cases of all genetically defined subgroups within a range of 0.5 to 10.8 years, except for tumors carrying KIAA1549-BRAF-fusions. Histone3-K27M-mutant tumors proved uniformly fatal within 0.6 to 2.4 years. The current LGG treatment strategy seems appropriate for all DG2-entities, with the exemption of Histone3-K27M-mutant tumors that require a HGG-related treatment strategy. Our data confirm the importance to genetically define pediatric low-grade diffuse gliomas for proper treatment decisions and risk assessment. 相似文献
5.
6.
7.
8.
9.
Nagaendran Kandiah Yee Fai Chan Christopher Chen Darwin Dasig Jacqueline Dominguez Seol-Heui Han Jianping Jia SangYun Kim Panita Limpawattana Li-Ling Ng Dinh Toan Nguyen Paulus Anam Ong Encarnita Raya-Ampil Nor'izzati Saedon Vorapun Senanarong Siti Setiati Harjot Singh Chuthamanee Suthisisang Tong Mai Trang Yuda Turana Narayanaswamy Venketasubramanian Fee Mann Yong Yong Chul Youn Ralf Ihl 《CNS Neuroscience & Therapeutics》2021,27(2):149-162
BackgroundMild cognitive impairment (MCI) is a neurocognitive state between normal cognitive aging and dementia, with evidence of neuropsychological changes but insufficient functional decline to warrant a diagnosis of dementia. Individuals with MCI are at increased risk for progression to dementia; and an appreciable proportion display neuropsychiatric symptoms (NPS), also a known risk factor for dementia. Cerebrovascular disease (CVD) is thought to be an underdiagnosed contributor to MCI/dementia. The Ginkgo biloba extract, EGb 761®, is increasingly being used for the symptomatic treatment of cognitive disorders with/without CVD, due to its known neuroprotective effects and cerebrovascular benefits.AimsTo present consensus opinion from the ASian Clinical Expert group on Neurocognitive Disorders (ASCEND) regarding the role of EGb 761® in MCI.Materials & MethodsThe ASCEND Group reconvened in September 2019 to present and critically assess the current evidence on the general management of MCI, including the efficacy and safety of EGb 761® as a treatment option.ResultsEGb 761® has demonstrated symptomatic improvement in at least four randomized trials, in terms of cognitive performance, memory, recall and recognition, attention and concentration, anxiety, and NPS. There is also evidence that EGb 761® may help delay progression from MCI to dementia in some individuals.DiscussionEGb 761® is currently recommended in multiple guidelines for the symptomatic treatment of MCI. Due to its beneficial effects on cerebrovascular blood flow, it is reasonable to expect that EGb 761® may benefit MCI patients with underlying CVD.ConclusionAs an expert group, we suggest it is clinically appropriate to incorporate EGb 761® as part of the multidomain intervention for MCI. 相似文献
10.
Lu Ping Tan Geok Wee Tan Vijaya Mohan Sivanesan Siang Ling Goh Xun Jin Ng Chun Shen Lim Wee Ric Kim Taznim Begam Binti Mohd Mohidin Nor Soleha Mohd Dali Siew Hoon Ong Chun Ying Wong Halimuddin Sawali Yoke Yeow Yap Faridah Hassan Kin Choo Pua Cheng Eng Koay Ching Ching Ng Alan Soo-Beng Khoo the Malaysian Nasopharyngeal Carcinoma Study Group 《International journal of cancer. Journal international du cancer》2020,146(8):2336-2347
Nasopharyngeal carcinoma (NPC) is originated from the epithelial cells of nasopharynx, Epstein–Barr virus (EBV)-associated and has the highest incidence and mortality rates in Southeast Asia. Late presentation is a common issue and early detection could be the key to reduce the disease burden. Sensitivity of plasma EBV DNA, an established NPC biomarker, for Stage I NPC is controversial. Most newly reported NPC biomarkers have neither been externally validated nor compared to the established ones. This causes difficulty in planning for cost-effective early detection strategies. Our study systematically evaluated six established and four new biomarkers in NPC cases, population controls and hospital controls. We showed that BamHI-W 76 bp remains the most sensitive plasma biomarker, with 96.7% (29/30), 96.7% (58/60) and 97.4% (226/232) sensitivity to detect Stage I, early stage and all NPC, respectively. Its specificity was 94.2% (113/120) against population controls and 90.4% (113/125) against hospital controls. Diagnostic accuracy of BamHI-W 121 bp and ebv-miR-BART7-3p were validated. Hsa-miR-29a-3p and hsa-miR-103a-3p were not, possibly due to lower number of advanced stage NPC cases included in this subset. Decision tree modeling suggested that combination of BamHI-W 76 bp and VCA IgA or EA IgG may increase the specificity or sensitivity to detect NPC. EBNA1 99 bp could identify NPC patients with poor prognosis in early and advanced stage NPC. Our findings provided evidence for improvement in NPC screening strategies, covering considerations of opportunistic screening, combining biomarkers to increase sensitivity or specificity and testing biomarkers from single sampled specimen to avoid logistic problems of resampling. 相似文献